Back to results
US 12,590,961 B2Granted
Quantum dot conjugated virus spike protein for cell-based bio-sensing systems and drug screening
AssigneeThe Government of the United States of America, as represented by the Secretary of the Navy
InventorsEunkeu Oh, Kimihiro Susumu, Mason A. Wolak, Kirill Gorshkov
Life of this patent
Estimating the term…
Abstract
Quantum dots conjugated to SARS-CoV-2 Spike protein receptor binding domain (RBD) interact with gold nanoparticles bound to angiotensin converting enzyme 2 (ACE2) and thus undergo energy transfer. This energy transfer indicates RBD/ACE binding and can be used to assay for inhibitors thereof. Moreover, these labeled quantum dots were found to undergo endocytosis in cells expressing ACE2.
Claims5
A method of assaying inhibitors of Spike protein binding, comprising:
- providing a quantum dot labeled with a protein comprising SARS-COV-2 Spike protein receptor binding domain (RBD) comprising a Spike protein trimer;
- contacting the quantum dot with a gold nanoparticle conjugated to angiotensin converting enzyme 2 (ACE2) in the presence of a possible inhibitor of binding between the RBD and ACE2;
- and
- measuring energy transfer between the quantum dot and the gold nanoparticle, wherein the energy transfer when compared to a control indicates binding between the RBD and ACE2 and thereby possible inhibition thereof.
1 more element
Dependencies are inferred from the claim text.